Modified chemokine receptor ccr-3 and assay
OwnerAshley Antony Barnes, Neil James Fraser +2inventors
InventorsAshley Antony Barnes, Neil James Fraser, Celestine Theresa O'Shaughnessy, Alan Wise
Life of this patent
Estimating the term…
Abstract
The present invention relates to the modification of the CC chemokine receptor 3 to stabilise or enhance surface expression, for example, to reduce internalization and/or kinase-mediated phosphorylation. The invention also relates to assays for CCR3 receptor activity in which internalization and/or kinase mediated phosphorylation of the receptor is reduced.
Claims19
A modified CCR3 receptor which has been modified to stabilise or enhance expression of the receptor in a cell membrane.
A modified CCR3 receptor according to any one of the preceding claims wherein the modification comprises or additionally comprises mutation or deletion of the internalization site YIPF at position 327-330 of SEQ ID No. 1 or an equivalent position of a variant CCR3 receptor.
A modified CCR3 receptor according to any one of the preceding claims wherein the modification comprises or additionally comprises an N-terminal signal sequence to enhance delivery of modified receptor to the cell surface.
A modified CCR3 receptor according to any one of the preceding claims comprising deletion and/or mutation of at least one phosphorylation site and deletion/mutation of an internalization site.
A modified CCR3 receptor according to any one of the preceding claims wherein the modification comprises deletion of the C-terminal region of the receptor at a position to remove all C-terminal phosphorylation sites and the internalization site.
A polynucleotide encoding a modified CCR3 receptor according to any one of the preceding claims.
Dependencies are inferred from the claim text.